BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14599408)

  • 1. [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].
    Teira R; Cámara MM; Escobar A; Muñoz P; López de Munain J; Santamaría JM
    Med Clin (Barc); 2003 Oct; 121(14):532-4. PubMed ID: 14599408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
    Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
    AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
    d'Arminio Monforte A; Testa L; Adorni F; Chiesa E; Bini T; Moscatelli GC; Abeli C; Rusconi S; Sollima S; Balotta C; Musicco M; Galli M; Moroni M
    AIDS; 1998 Sep; 12(13):1631-7. PubMed ID: 9764782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
    Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
    HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
    Kirk O; Mocroft A; Pradier C; Bruun JN; Hemmer R; Clotet B; Miller V; Viard JP; Phillips AN; Lundgren JD;
    AIDS; 2001 May; 15(8):999-1008. PubMed ID: 11399982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
    Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
    J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
    Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
    AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.
    Eiros Bouza JM; Ortega M; Ortiz de Lejarazu R; Blanco R; Bachiller P; de Luis DA
    Int J Antimicrob Agents; 2004 Mar; 23(3):304-6. PubMed ID: 15164974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors.
    Gatanaga H; Aizawa S; Kikuchi Y; Tachikawa N; Genka I; Yoshizawa S; Yamamoto Y; Yasuoka A; Oka S
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1493-8. PubMed ID: 10580399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
    Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
    AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.